Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell'
CNBC-TV18

Gland Pharma shares surged 7 percent to a 52-week high following contrasting analyst views from Nomura and Citi.
Gland Pharma shares jumped 7 percent to a 52-week high as analysts offered mixed outlooks. Nomura expects a valuation re-rating driven by strong Q2FY27 performance, US market momentum, and a shift toward CDMO operations. Conversely, Citi maintained a sell rating on the stock.
Why it matters: Conflicting analyst recommendations from Nomura and Citi highlight differing market perspectives on Gland Pharma's ongoing business model transition toward CDMO operations and its recent financial performance.









